NCT07464756 2026-03-11
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
Clinical Trials
213 trialsNCT06519591 2026-02-18
Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
Ruijin Hospital
Phase 2 Recruiting
NCT06693128 2026-01-28
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Ruijin Hospital
Phase 2 Active not recruiting
NCT06510010 2026-01-26
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT07366528 2026-01-26
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Ruijin Hospital
Phase 3 Recruiting
NCT04208347 2026-01-23
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Ruijin Hospital
Phase 2/3 Active not recruiting
NCT05026905 2026-01-20
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Active not recruiting
NCT07038629 2026-01-07
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT03443492 2025-12-30
Pancreas
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT07304258 2025-12-26
A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
Hebei Medical University
Phase 2 Not yet recruiting
NCT03013010 2025-12-08
PREACT
Shanghai Cancer Hospital, China
Phase 3 Completed
NCT06584227 2025-12-08
ACPC
Jinling Hospital, China
Phase 2 Recruiting
NCT07243938 2025-11-24
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07194005 2025-09-26
Remission
Fudan University
Phase 2 Recruiting
NCT07070479 2025-09-18
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT07007182 2025-09-05
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT05773092 2025-09-03
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT06732856 2025-07-28
NEO-CLAUD
Asan Medical Center
Phase 1/2 Recruiting
NCT06048913 2025-07-04
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Completed
NCT07025889 2025-06-18
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Ruijin Hospital
Phase 1/2 Recruiting
NCT07018063 2025-06-12
YOUNG-NEOS
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT06988956 2025-05-25
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06779318 2025-04-03
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
The First Affiliated Hospital with Nanjing Medical University
Phase 4 Not yet recruiting
NCT04195828 2025-04-01
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
Fujian Medical University
Phase 2 Completed
NCT06901622 2025-03-30
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Enrolling by invitation
NCT06881017 2025-03-18
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
China Medical University, China
Phase 2 Not yet recruiting
NCT04863430 2025-02-21
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Peking University
Phase 2 Withdrawn
NCT05586061 2025-02-07
RCTS
Qilu Hospital of Shandong University
Phase 2 Active not recruiting
NCT06789679 2025-01-30
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06427005 2025-01-22
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
West China Hospital
Phase 2 Recruiting
NCT06657690 2025-01-10
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Sun Yat-sen University
Phase 2 Recruiting
NCT05218889 2024-12-31
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT03878472 2024-12-16
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Phase 2 Completed
NCT02867839 2024-12-03
RESCUE-GC
Peking University Cancer Hospital & Institute
Phase 3 Terminated
NCT06662877 2024-10-29
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Sun Yat-sen University
Phase 2/3 Not yet recruiting
NCT06598917 2024-09-19
Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT
China Medical University Hospital
Phase 2 Not yet recruiting
NCT06487429 2024-07-05
Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06487715 2024-07-05
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Enrolling by invitation
NCT06454435 2024-06-12
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06451211 2024-06-11
Neo-ICEBOAT
Sun Yat-sen University
Phase 2 Recruiting
NCT06447636 2024-06-07
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT04207918 2024-05-16
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT06385873 2024-05-13
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06383078 2024-04-25
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06341595 2024-04-02
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05048524 2024-03-27
Peri-operative SLOG for Localized Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Recruiting
NCT06187597 2024-03-12
EC-CRT-007
Sun Yat-sen University
Phase 2 Recruiting
NCT05184803 2024-02-28
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
Asan Medical Center
Phase 2 Unknown
NCT04694183 2024-02-07
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
The First Hospital of Jilin University
Phase 2 Completed